what does glp 1 do GLP-1 Agonists - is it? Navigating the Limitations and Downsides

Inflammation is the primary pathological mechanism underlying CAD, since is involved in atherosclerotic plaque formation

Combining weight loss medications increases the risk of side effects and is absolutely not suitable for everyone

As of now, GLP-1-related triple agonists are primarily still in the development stage and have not been widely approved for use

On average, volunteers in the retatrutide clinical trial who received the study drug rather than a placebo lost an average of 70.3 pounds over about a year-and-a-half, with more than 45% of participants losing more than 30% of their body weight

Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E

GLP-1 drugs, formally called glucagon-like peptide-1 receptor agonists, are incretin-based therapies that activate the GLP-1 receptor